Each week we highlight five things affecting the life sciences industry. Here's the latest. Biden administration receives counteroffers from drug companies The Biden administration has received counteroffers from drug manufacturers in Medicare price negotiations under the Inflation Reduction Act, ... READ MORE >
CROs
5 things to know in life sciences: Week of May 2, 2022
This week we highlight a series of moves by the Food and Drug Administration related to COVID-19 treatments, Alzheimer's and CBD. We also look at contract research organizations and a robotics manufacturing partnership in cell and gene therapy, as well as sentiment in the biotech funding space. Each week ... READ MORE >
5 things to know in life sciences: Week of April 4, 2022
This week we highlight a slow start to the year for life sciences initial public offerings, Medicare’s decision on Alzheimer’s disease reimbursement, the use of machine learning and artificial intelligence in clinical trials and the rapidly growing market for virtual trials. Finally, we look at how the ... READ MORE >
5 things to know in life sciences: Week of March 21, 2022
This week we highlight continued investment in virtual trials, robotic injections, costs of COVID-19 treatments and the need to understand drug safety for pregnant patients. Finally, we look at the most recent round of drug pricing reform in Congress which aims to reduce insulin prices. Each week we ... READ MORE >
Clinical trials and life sciences services: Spring 2022 outlook
While there has been a downward trend in COVID-19 clinical trial starts, these trials maintain strong momentum into 2022. Enrollment remains at the top of the list of challenges facing clinical trials. Virtual trial companies have seen exponential growth over the past two quarters. Read about ... READ MORE >